Chander Vikas, Chopra Kanwaijit
Pharmacology Division, University Institute of Pharmaceutical Sciences, Panjab University, Chandigarh, India.
Ren Fail. 2005;27(4):441-50.
Cyclosporine A (CsA) is a potent and effective immunosuppressive agent, but its action is frequently accompanied by severe renal toxicity. The causes for the nephrotoxicity of CsA have not been fully elucidated. Intrarenal vasoconstriction induced by several different mediators, both in humans and experimental animals, have been proposed. To determine if the renal alterations are mediated directly by cyclosporine or by secondary hemodynamic alterations induced by cyclosporine, we evaluated if nifedipine prevents these alterations. Eight groups of rats were employed in this study, group 1 served as control, group 2 rats were treated with CsA (20 mg/mL, s.c. for 21 days), groups 3, 4, and 5 received CsA along with various doses of nifedipine (5, 10, and 20 mg/kg, p.o.) 24 h before and 21 days concurrently, groups 6, 7, and 8 received L-NAME (10 mg/kg i.p.), propranolol (10 mg/kg i.p.), and aminoguanidine (100 mg/kg p.o.), respectively, along with CsA. Renal function was assessed by measuring serum creatinine, blood urea nitrogen, creatinine, and urea clearance. Tissue and urine nitrite and nitrate levels were measured to estimate the total nitric oxide levels. The renal oxidative stress was measured by renal malondialdehyde levels, reduced glutathione levels, and enzymatic activity of catalase and superoxide dismutase. Renal morphological alterations were assessed by histopathological examination. CsA administration for 21 days resulted in a marked renal oxidative stress, and significantly deranged the renal functions as well as renal morphology. Treatment with nifedipine (10, 20 mg/kg) significantly improved the renal dysfunction, tissue and urine total nitric oxide levels, and renal oxidative stress and prevented the alterations in renal morphology. These results clearly demonstrate that nifedipine is beneficial as a protective agent against nephrotoxicity induced by CsA, and the protection afforded by nifedipine appears to be mediated by an increase in endothelial nitric oxide release.
环孢素A(CsA)是一种强效且有效的免疫抑制剂,但其作用常常伴有严重的肾毒性。CsA肾毒性的原因尚未完全阐明。在人类和实验动物中,均有人提出是由几种不同介质诱导的肾内血管收缩所致。为了确定肾脏改变是由环孢素直接介导还是由环孢素诱导的继发性血流动力学改变介导,我们评估了硝苯地平是否能预防这些改变。本研究使用了八组大鼠,第1组作为对照,第2组大鼠用CsA治疗(20 mg/mL,皮下注射21天),第3、4和5组在同时给予CsA的前24小时及21天期间,分别口服不同剂量的硝苯地平(5、10和20 mg/kg),第6、7和8组分别与CsA一起腹腔注射L - NAME(10 mg/kg)、普萘洛尔(10 mg/kg)和口服氨基胍(100 mg/kg)。通过测量血清肌酐、血尿素氮、肌酐和尿素清除率来评估肾功能。测量组织和尿液中亚硝酸盐和硝酸盐水平以估计总一氧化氮水平。通过肾丙二醛水平、还原型谷胱甘肽水平以及过氧化氢酶和超氧化物歧化酶的酶活性来测量肾脏氧化应激。通过组织病理学检查评估肾脏形态学改变。给予CsA 21天导致明显的肾脏氧化应激,并显著扰乱了肾功能以及肾脏形态。用硝苯地平(10、20 mg/kg)治疗可显著改善肾功能障碍、组织和尿液总一氧化氮水平以及肾脏氧化应激,并预防肾脏形态学改变。这些结果清楚地表明,硝苯地平作为一种预防CsA诱导的肾毒性的保护剂是有益的,并且硝苯地平提供的保护似乎是由内皮一氧化氮释放增加介导的。